Published in Am J Respir Cell Mol Biol on October 29, 2010
An endothelial apelin-FGF link mediated by miR-424 and miR-503 is disrupted in pulmonary arterial hypertension. Nat Med (2012) 2.59
Dysregulated renin-angiotensin-aldosterone system contributes to pulmonary arterial hypertension. Am J Respir Crit Care Med (2012) 2.52
Inflammation and immunity in the pathogenesis of pulmonary arterial hypertension. Circ Res (2014) 1.38
Genome-wide association analysis identifies a susceptibility locus for pulmonary arterial hypertension. Nat Genet (2013) 1.11
MicroRNAs in pulmonary arterial remodeling. Cell Mol Life Sci (2013) 0.99
Inhibition of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) reverses experimental pulmonary hypertension. J Exp Med (2012) 0.97
Copper dependence of angioproliferation in pulmonary arterial hypertension in rats and humans. Am J Respir Cell Mol Biol (2011) 0.93
MicroRNAs in pulmonary arterial hypertension. Am J Respir Cell Mol Biol (2015) 0.90
Anticipated classes of new medications and molecular targets for pulmonary arterial hypertension. Pulm Circ (2013) 0.90
Key role of the endothelial TGF-β/ALK1/endoglin signaling pathway in humans and rodents pulmonary hypertension. PLoS One (2014) 0.88
Translating Research into Improved Patient Care in Pulmonary Arterial Hypertension. Am J Respir Crit Care Med (2016) 0.84
A novel p38 mitogen-activated protein kinase/Elk-1 transcription factor-dependent molecular mechanism underlying abnormal endothelial cell proliferation in plexogenic pulmonary arterial hypertension. J Biol Chem (2013) 0.83
Right ventricular systolic pressure measurements in combination with harvest of lung and immune tissue samples in mice. J Vis Exp (2013) 0.81
A critical role for p130Cas in the progression of pulmonary hypertension in humans and rodents. Am J Respir Crit Care Med (2012) 0.79
Fibroblast Growth Factor-2 and the HIV-1 Tat Protein Synergize in Promoting Bcl-2 Expression and Preventing Endothelial Cell Apoptosis: Implications for the Pathogenesis of AIDS-Associated Kaposi's Sarcoma. Int J Vasc Med (2011) 0.79
Adenosine A2A receptor-dependent proliferation of pulmonary endothelial cells is mediated through calcium mobilization, PI3-kinase and ERK1/2 pathways. Biochem Biophys Res Commun (2013) 0.78
Dasatinib induces lung vascular toxicity and predisposes to pulmonary hypertension. J Clin Invest (2016) 0.78
Epidemiology and treatment of pulmonary arterial hypertension. Nat Rev Cardiol (2017) 0.75
Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol (2009) 12.05
Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer (2010) 8.55
Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J Biol Chem (1998) 8.30
Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J (2009) 6.64
Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol (2004) 5.79
Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest (2005) 4.74
MAPK signal pathways in the regulation of cell proliferation in mammalian cells. Cell Res (2002) 3.97
Inflammation, growth factors, and pulmonary vascular remodeling. J Am Coll Cardiol (2009) 3.75
A heparin-binding angiogenic protein--basic fibroblast growth factor--is stored within basement membrane. Am J Pathol (1988) 3.72
Cellular and molecular basis of pulmonary arterial hypertension. J Am Coll Cardiol (2009) 3.69
Molecular and cellular aspects of the insulin-like growth factor I receptor. Endocr Rev (1995) 3.58
Hyperproliferative apoptosis-resistant endothelial cells in idiopathic pulmonary arterial hypertension. Am J Physiol Lung Cell Mol Physiol (2007) 3.28
An antiproliferative BMP-2/PPARgamma/apoE axis in human and murine SMCs and its role in pulmonary hypertension. J Clin Invest (2008) 2.71
Gene therapy targeting survivin selectively induces pulmonary vascular apoptosis and reverses pulmonary arterial hypertension. J Clin Invest (2005) 2.32
Dichloroacetate prevents and reverses pulmonary hypertension by inducing pulmonary artery smooth muscle cell apoptosis. Circ Res (2004) 2.06
Cross talk between endothelial and smooth muscle cells in pulmonary hypertension: critical role for serotonin-induced smooth muscle hyperplasia. Circulation (2006) 1.79
Endothelial-derived FGF2 contributes to the progression of pulmonary hypertension in humans and rodents. J Clin Invest (2009) 1.65
Bcl-2 and Bcl-XL can differentially block chemotherapy-induced cell death. Blood (1997) 1.54
Basic fibroblast growth factor protects endothelial cells against radiation-induced programmed cell death in vitro and in vivo. Cancer Res (1994) 1.50
Tie2-mediated loss of peroxisome proliferator-activated receptor-gamma in mice causes PDGF receptor-beta-dependent pulmonary arterial muscularization. Am J Physiol Lung Cell Mol Physiol (2009) 1.47
Serotonin transporter inhibition prevents and reverses monocrotaline-induced pulmonary hypertension in rats. Circulation (2005) 1.40
Endothelial cells and pulmonary arterial hypertension: apoptosis, proliferation, interaction and transdifferentiation. Respir Res (2009) 1.35
Bcl-XL is qualitatively different from and ten times more effective than Bcl-2 when expressed in a breast cancer cell line. BMC Cancer (2006) 1.33
Fibroblast growth factors: an epigenetic mechanism of broad spectrum resistance to anticancer drugs. Proc Natl Acad Sci U S A (2000) 1.32
Angiopoietin/Tie2 pathway influences smooth muscle hyperplasia in idiopathic pulmonary hypertension. Am J Respir Crit Care Med (2006) 1.29
Protein kinase C mediates basic fibroblast growth factor protection of endothelial cells against radiation-induced apoptosis. Cancer Res (1994) 1.26
Epidermal growth factor receptor-dependent control of keratinocyte survival and Bcl-xL expression through a MEK-dependent pathway. J Biol Chem (2000) 1.21
Insulin-like growth factor-I induces bcl-2 promoter through the transcription factor cAMP-response element-binding protein. J Biol Chem (1999) 1.21
Activation of the Bcl-2 promoter by nerve growth factor is mediated by the p42/p44 MAPK cascade. Nucleic Acids Res (1999) 1.16
Basic fibroblast growth factor (bFGF) upregulates the expression of bcl-2 in B cell chronic lymphocytic leukemia cell lines resulting in delaying apoptosis. Leukemia (1997) 1.14
Janus face of vascular endothelial growth factor: the obligatory survival factor for lung vascular endothelium controls precapillary artery remodeling in severe pulmonary hypertension. Crit Care Med (2002) 1.03
Effect of PPARgamma inhibition on pulmonary endothelial cell gene expression: gene profiling in pulmonary hypertension. Physiol Genomics (2009) 1.02
The role of antiapoptotic Bcl-2 family members in endothelial apoptosis elucidated with antisense oligonucleotides. J Biol Chem (1999) 1.02
Dichloroacetate treatment partially regresses established pulmonary hypertension in mice with SM22alpha-targeted overexpression of the serotonin transporter. FASEB J (2009) 1.00
Heparan sulfate primed on beta-D-xylosides restores binding of basic fibroblast growth factor. J Cell Biochem (1995) 0.99
Endothelium-targeted overexpression of constitutively active FGF receptor induces cardioprotection in mice myocardial infarction. J Mol Cell Cardiol (2009) 0.93
Both FGF1 and bcl-x synthesis are necessary for the reduction of apoptosis in retinal pigmented epithelial cells by FGF2: role of the extracellular signal-regulated kinase 2. Oncogene (1999) 0.91
Low level expression of basic FGF upregulates Bcl-2 and delays apoptosis, but high intracellular levels are required to induce transformation in NIH 3T3 cells. Growth Factors (1997) 0.88
Activation of the FGF2/FGFR1 autocrine loop for cell proliferation and survival in uveal melanoma cells. Invest Ophthalmol Vis Sci (2008) 0.86
Laying the foundations of programmed cell death. Cell Death Differ (2006) 0.77
Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med (2005) 9.27
Treatment of pulmonary arterial hypertension. N Engl J Med (2004) 6.88
2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J (2014) 6.32
Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med (2006) 6.06
Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation (2010) 5.87
Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med (2013) 5.60
Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med (2013) 4.98
Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol (2002) 4.79
Inflammation, growth factors, and pulmonary vascular remodeling. J Am Coll Cardiol (2009) 3.75
Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Eur Heart J (2004) 3.51
Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med (2014) 3.50
Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study. Arthritis Rheum (2005) 3.44
Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation (2005) 2.98
Pathologic assessment of vasculopathies in pulmonary hypertension. J Am Coll Cardiol (2004) 2.93
Pulmonary arterial hypertension in patients treated by dasatinib. Circulation (2012) 2.87
Role for interleukin-6 in COPD-related pulmonary hypertension. Chest (2009) 2.73
An antiproliferative BMP-2/PPARgamma/apoE axis in human and murine SMCs and its role in pulmonary hypertension. J Clin Invest (2008) 2.71
Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study. Circulation (2013) 2.64
Chronic thromboembolic pulmonary hypertension. Circulation (2006) 2.58
Dysregulated renin-angiotensin-aldosterone system contributes to pulmonary arterial hypertension. Am J Respir Crit Care Med (2012) 2.52
Platelet-derived growth factor expression and function in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med (2008) 2.48
New formula for predicting mean pulmonary artery pressure using systolic pulmonary artery pressure. Chest (2004) 2.47
Is pulmonary arterial hypertension really a late complication of systemic sclerosis? Chest (2009) 2.40
Apoptosis and effects of intracavernous bone marrow cell injection in a rat model of postprostatectomy erectile dysfunction. Eur Urol (2008) 2.38
Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension. Eur Heart J (2006) 2.34
Vascular and right ventricular remodelling in chronic thromboembolic pulmonary hypertension. Eur Respir J (2012) 2.32
Mutations of the TGF-beta type II receptor BMPR2 in pulmonary arterial hypertension. Hum Mutat (2006) 2.30
Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension. N Engl J Med (2015) 2.23
CX(3)C chemokine fractalkine in pulmonary arterial hypertension. Am J Respir Crit Care Med (2002) 2.15
C-kit-positive cells accumulate in remodeled vessels of idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med (2011) 2.12
Transgenic mice overexpressing the 5-hydroxytryptamine transporter gene in smooth muscle develop pulmonary hypertension. Circ Res (2006) 2.10
Clinical outcomes of pulmonary arterial hypertension in carriers of BMPR2 mutation. Am J Respir Crit Care Med (2008) 2.09
T-helper 17 cell polarization in pulmonary arterial hypertension. Chest (2015) 2.09
Graft ischemic time and outcome of lung transplantation: a multicenter analysis. Am J Respir Crit Care Med (2005) 2.08
Pulmonary arterial remodeling induced by a Th2 immune response. J Exp Med (2008) 2.08
Validation of a scoring system to predict recurrence of resected solitary fibrous tumors of the pleura. Chest (2015) 2.04
Prevalence of HIV-related pulmonary arterial hypertension in the current antiretroviral therapy era. Am J Respir Crit Care Med (2007) 2.03
Retrospective institutional study of 31 patients treated for pulmonary artery sarcoma. Eur J Cardiothorac Surg (2012) 1.97
Serotonin-induced smooth muscle hyperplasia in various forms of human pulmonary hypertension. Circ Res (2004) 1.92
Proinflammatory cytokine levels are linked to death in pulmonary arterial hypertension. Eur Respir J (2013) 1.92
Chronic thromboembolic pulmonary hypertension (CTEPH): results from an international prospective registry. Circulation (2011) 1.92
Functional defect of regulatory CD4(+)CD25+ T cells in the thymus of patients with autoimmune myasthenia gravis. Blood (2004) 1.90
Severe pulmonary hypertension during pregnancy: mode of delivery and anesthetic management of 15 consecutive cases. Anesthesiology (2005) 1.88
Developmental expression of LC3alpha and beta: absence of fibronectin or autophagy phenotype in LC3beta knockout mice. Dev Dyn (2008) 1.88
Severe asthma in adults: what are the important questions? J Allergy Clin Immunol (2007) 1.85
Ambrisentan therapy for pulmonary arterial hypertension. J Am Coll Cardiol (2005) 1.82
Cross talk between endothelial and smooth muscle cells in pulmonary hypertension: critical role for serotonin-induced smooth muscle hyperplasia. Circulation (2006) 1.79
Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol (2002) 1.77
Survival and prognostic factors in systemic sclerosis-associated pulmonary hypertension: a systematic review and meta-analysis. Arthritis Rheum (2013) 1.73
Treprostinil, a prostacyclin analogue, in pulmonary arterial hypertension associated with connective tissue disease. Chest (2004) 1.72
Portopulmonary hypertension: survival and prognostic factors. Am J Respir Crit Care Med (2008) 1.71
Sternal resection and reconstruction for primary malignant tumors. Ann Thorac Surg (2004) 1.71
Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension: a 1-year follow-up study. Chest (2003) 1.71
Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT (Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial. J Am Coll Cardiol (2008) 1.69
BMPR2 gene rearrangements account for a significant proportion of mutations in familial and idiopathic pulmonary arterial hypertension. Hum Mutat (2006) 1.69
Pulmonary Langerhans cell histiocytosis-associated pulmonary hypertension: clinical characteristics and impact of pulmonary arterial hypertension therapies. Chest (2012) 1.68
Surgical management and outcome of patients with chronic thromboembolic pulmonary hypertension: results from an international prospective registry. J Thorac Cardiovasc Surg (2011) 1.66
Morbidity, mortality, and long-term survival after sleeve lobectomy for non-small cell lung cancer. Eur J Cardiothorac Surg (2006) 1.65
Endothelial-derived FGF2 contributes to the progression of pulmonary hypertension in humans and rodents. J Clin Invest (2009) 1.65
Pregnancy outcomes in pulmonary arterial hypertension in the modern management era. Eur Respir J (2012) 1.63
Selexipag for the Treatment of Pulmonary Arterial Hypertension. N Engl J Med (2015) 1.62
2015 ESC/ERS Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension. Rev Esp Cardiol (Engl Ed) (2016) 1.61
Intravenous epoprostenol in inoperable chronic thromboembolic pulmonary hypertension. J Heart Lung Transplant (2007) 1.58